Jennison Associates LLC Increases Position in uniQure N.V. $QURE

Jennison Associates LLC lifted its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 37.2% during the fourth quarter, Holdings Channel reports. The fund owned 1,371,190 shares of the biotechnology company’s stock after purchasing an additional 371,706 shares during the quarter. Jennison Associates LLC’s holdings in uniQure were worth $32,813,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Jones Financial Companies Lllp increased its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System increased its holdings in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 627 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the last quarter. Finally, CIBC Private Wealth Group LLC bought a new stake in uniQure in the third quarter valued at about $50,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, April 20th. Leerink Partners reissued an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. Barclays lowered their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Finally, Chardan Capital boosted their price objective on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.33.

uniQure Trading Down 4.1%

NASDAQ QURE opened at $19.13 on Friday. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a 50-day simple moving average of $16.75 and a 200-day simple moving average of $26.01. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The firm has a market capitalization of $1.21 billion, a PE ratio of -5.54 and a beta of 0.75.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. The company had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, equities analysts forecast that uniQure N.V. will post -3.6 earnings per share for the current year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at $5,985,561.48. This represents a 2.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jeannette Potts sold 3,412 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares of the company’s stock, valued at $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 49,396 shares of company stock valued at $722,734. 4.79% of the stock is currently owned by insiders.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported a successful pre-submission meeting with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for AMT‑130 and said it expects to submit a U.K. Marketing Authorization Application in Q3 2026 — a clear pathway to pursue approval outside the U.S. and a major near-term regulatory milestone. uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130
• Positive Sentiment: Market coverage and outlets reported an immediate positive market reaction to the U.K. update (coverage noted intraday gains), reflecting investor optimism that a U.K. approval route could salvage commercial prospects after prior U.S. regulatory friction. QURE stock just shot up 8% – MSN
• Positive Sentiment: Analyst support: Chardan Capital raised its price target from $31 to $37 and reiterated a “buy” rating, increasing upside expectations and likely supporting bullish sentiment. Benzinga Coverage of Chardan PT Raise
• Neutral Sentiment: Corporate calendar: uniQure is expected to announce quarterly earnings on Tuesday — this event could amplify short-term volatility as investors reassess guidance, cash burn and program timelines. Earnings Date Notice
• Negative Sentiment: Regulatory risk remains material: coverage highlights prior disagreements with the U.S. FDA over AMT‑130; while the U.K. route is promising, successful MHRA interactions don’t eliminate the possibility of later setbacks or additional data requirements. Biospace on FDA Quarrel and UK Strategy
• Negative Sentiment: Fundamental risks: uniQure remains loss-making with limited current revenue, making its valuation highly sensitive to regulatory and commercial outcomes for AMT‑130 and other pipeline assets. (Refer to recent financials for full detail.)

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.